Ginkgo Bioworks Holdings Inc (DNA)
7.285
-1.32
(-15.29%)
USD |
NYSE |
Nov 14, 16:00
7.37
+0.08
(+1.17%)
After-Hours: 20:00
Ginkgo Bioworks Holdings Revenue (Quarterly): 56.21M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 56.21M |
| March 31, 2024 | 37.94M |
| December 31, 2023 | 34.76M |
| September 30, 2023 | 55.43M |
| June 30, 2023 | 80.57M |
| March 31, 2023 | 80.70M |
| December 31, 2022 | 98.28M |
| September 30, 2022 | 66.40M |
| Date | Value |
|---|---|
| June 30, 2022 | 144.62M |
| March 31, 2022 | 168.40M |
| December 31, 2021 | 148.49M |
| September 30, 2021 | 77.61M |
| June 30, 2021 | 43.64M |
| March 31, 2021 | 44.10M |
| December 31, 2020 | 32.06M |
| September 30, 2020 | 13.30M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
13.30M
Minimum
Sep 2020
168.40M
Maximum
Mar 2022
73.91M
Average
61.30M
Median
Revenue (Quarterly) Benchmarks
| Boston Scientific Corp | 4.209B |
| UnitedHealth Group Inc | 99.18B |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.05M |
| IGC Pharma Inc | 0.272M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -217.18M |
| Total Expenses (Quarterly) | 214.23M |
| EPS Diluted (Quarterly) | -4.40 |
| Enterprise Value | -252.42M |
| Gross Profit Margin (Quarterly) | 75.59% |
| Profit Margin (Quarterly) | -386.4% |
| Earnings Yield | -252.6% |
| Normalized Earnings Yield | -188.25 |